Comparative Pharmacology
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus VIVIMUSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELPHALAN HYDROCHLORIDE versus VIVIMUSTA.
MELPHALAN HYDROCHLORIDE vs VIVIMUSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
VIVIMUSTA is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
100 mg/m2 intravenously over 30 minutes on days 1-3 of a 21-day cycle.
None Documented
None Documented
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min).
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category D/X
Category C
Alkylating Agent
Alkylating Agent